ProCE Banner Activity

CE / CME

Advances in IBD Precision Medicine With Therapeutic Drug Monitoring

Multimedia

In this engaging, interactive, on-demand webcast, expert faculty review the rationale and current best practices for therapeutic drug monitoring (TDM) in patients with IBD. The data-driven discussion includes proactive and reactive TDM approaches for both TNF inhibitors and non-TNF inhibitor biologics.

Physicians: maximum of 1.00 AMA PRA Category 1 CreditTM

Nurses: 1.00 Nursing contact hour

Released: February 16, 2022

Expiration: February 15, 2023

No longer available for credit.

Share

Faculty

Marla Dubinsky

Marla Dubinsky, MD

Professor of Pediatrics and Medicine
Chief, Division of Pediatric Gastroenterology and Nutrition
Co-Director, Susan and Leonard Feinstein IBD Clinical Center
Mount Sinai Kravis Children’s Hospital
Ichan School of Medicine, Mount Sinai New York
New York, New York

Bruce E. Sands

Bruce E. Sands, MD, MS

Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Chief, Division of Gastroenterology
Mount Sinai Health System
New York, New York

Provided by

Provided by the American Gastroenterology Association.

ProCE Banner

Supporters

Supported by educational grants from

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This program is intended for gastroenterologists, nurse practitioners, nurses, and other healthcare providers who treat patients with IBD.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the likelihood of nonresponse/loss of response with biologic therapy and the mechanisms by which these treatment failures occur
  • Define TDM regarding biologics and describe appropriate treatment changes based on TDM results
  • Review current guideline recommendations for TDM of TNF inhibitors and the latest evidence for TDM in non-TNF inhibitor biologics

Faculty Disclosure

Primary Author

Marla Dubinsky, MD

Professor of Pediatrics and Medicine
Chief, Division of Pediatric Gastroenterology and Nutrition
Co-Director, Susan and Leonard Feinstein IBD Clinical Center
Mount Sinai Kravis Children’s Hospital
Ichan School of Medicine, Mount Sinai New York
New York, New York

Marla C. Dubinsky, MD, has disclosed that she has received consulting fees from AbbVie, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, F. Hoffmann-La Roche, Genentech, Gilead Sciences, Janssen, Lilly, Pfizer, Prometheus, Takeda, and UCB; funds for research support from AbbVie, Janssen, Pfizer, and Prometheus; has ownership interest and intellectual property rights in Trellus Health; and has received other financial or material support from Takeda.

Bruce E. Sands, MD, MS

Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
Chief, Division of Gastroenterology
Mount Sinai Health System
New York, New York

Bruce E. Sands, MD, MS, AGAF, has disclosed that he has received consulting fees from 4D Pharma, Abivax, AbbVie, Alimentiv, Allergan, Amgen, Arena, AstraZeneca, Bacainn, Boehringer-Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Calibr, Capella, Celgene, Celltrion, ClostraBio, Enthera, F.Hoffmann-La Roche, Ferring, Galapagos, Gilead, Glaxo SmithKline, GossamerBio, Immunic, Index, Innovation, Ironwood, Janssen, Kaleido, Kallyope, Lilly, MiroBio, Morphic, Oppilan, OSE, Otsuka, Palatin, Pfizer, Progenity, Prometheus, Protagonist, Q32 Bio, Redhill, Rheos, Salix, Seres, Shire, Sienna, Sun Pharma, Surrozen, Takeda, Target PharmaSolutions, Teva, Thelium, Theravance, TLL Pharma, USWM Enterprises, Ventyx, Viela Bio, Vivante, and Vivelix; funds for research support from Takeda, Pfizer, Theravance, and Janssen; and has ownership interest in Ventyx and Vivante.

Staff Disclosure

Staff

Craig Borders,

Vice President, Managing Scientific Director

Craig Borders has no relevant conflicts of interest to report.

Ruth Cohen,

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Laurie Powers, RN

Laurie Powers, RN has no relevant conflicts of interest to report

Instructions for Credit

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The AGA Institute designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and the American Gastroenterological Association. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 16, 2022, through February 15, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this education project is to increase the learners’ knowledge and competence in utilizing TDM to maximize the effectiveness of IBD therapies and help ensure long-term remission.